Halozyme Therapeutics, Inc. (NASDAQ: HALO) a California-based biopharmaceutical company, announced on Tuesday its financial results for the first quarter ended 31 March 2023.

The company reported revenue in the first quarter of 2023 at USD162.1m compared to USD117.3m for the year-ago period.

Halozyme Therapeutics posted operating income in the first quarter of 2023 at USD53.8m compared to operating income of USD75.7m for the same period in 2022.

The company reported diluted earnings per share of USD0.29 on a GAAP basis in the first quarter of 2023 compared to USD0.43 for the year-ago period. It posted diluted earnings per share of USD0.47 on a non-GAAP basis against diluted earnings per share of USD0.47 for the same period in 2022.